Ascendiant Capital Maintains Buy Rating on Plus Therapeutics, PT Down to $19

viernes, 21 de noviembre de 2025, 6:02 am ET1 min de lectura
PSTV--

Ascendiant Capital Maintains Buy Rating on Plus Therapeutics, PT Down to $19

Ascendiant Capital Maintains Buy Rating on Plus Therapeutics, PT Down to $19

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios